| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Practice Guidelines as Topic | 22 | 2024 | 1063 | 4.950 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 441 | 1.320 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 179 | 0.850 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 751 | 0.850 |
Why?
|
| Hypoglycemia | 1 | 2024 | 110 | 0.850 |
Why?
|
| Ambulatory Care | 1 | 2024 | 189 | 0.810 |
Why?
|
| Ferritins | 1 | 2021 | 29 | 0.770 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 20 | 0.760 |
Why?
|
| Humans | 63 | 2024 | 91074 | 0.730 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 99 | 0.690 |
Why?
|
| Macrolides | 1 | 2020 | 30 | 0.690 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 22 | 0.690 |
Why?
|
| beta-Lactams | 1 | 2020 | 14 | 0.680 |
Why?
|
| Smoking Prevention | 2 | 2016 | 46 | 0.670 |
Why?
|
| Lubricants | 1 | 2019 | 7 | 0.670 |
Why?
|
| Laxatives | 1 | 2019 | 13 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2018 | 1204 | 0.670 |
Why?
|
| Testosterone | 2 | 2018 | 272 | 0.670 |
Why?
|
| Menorrhagia | 1 | 2020 | 26 | 0.650 |
Why?
|
| Smoking Cessation | 3 | 2016 | 265 | 0.650 |
Why?
|
| Pneumonia | 1 | 2020 | 185 | 0.600 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2018 | 18 | 0.600 |
Why?
|
| Hair Removal | 1 | 2018 | 14 | 0.600 |
Why?
|
| Hirsutism | 1 | 2018 | 61 | 0.590 |
Why?
|
| Incidental Findings | 1 | 2018 | 99 | 0.590 |
Why?
|
| Algorithms | 2 | 2017 | 1933 | 0.590 |
Why?
|
| Hypogonadism | 1 | 2018 | 40 | 0.580 |
Why?
|
| Gender Dysphoria | 1 | 2017 | 10 | 0.580 |
Why?
|
| Aftercare | 1 | 2018 | 88 | 0.580 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 50 | 0.580 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 138 | 0.570 |
Why?
|
| Mass Screening | 4 | 2015 | 646 | 0.570 |
Why?
|
| Physician-Patient Relations | 4 | 2020 | 627 | 0.570 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 43 | 0.570 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 387 | 0.560 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 27 | 0.560 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 139 | 0.560 |
Why?
|
| Organizations | 1 | 2017 | 17 | 0.550 |
Why?
|
| Travel | 1 | 2017 | 72 | 0.550 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 162 | 0.540 |
Why?
|
| Diarrhea | 1 | 2017 | 178 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2711 | 0.530 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 276 | 0.520 |
Why?
|
| Thyroid Nodule | 1 | 2017 | 62 | 0.520 |
Why?
|
| Shock, Septic | 1 | 2017 | 105 | 0.510 |
Why?
|
| Health Services for the Aged | 1 | 2015 | 32 | 0.500 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 258 | 0.500 |
Why?
|
| Hepatitis C Antibodies | 1 | 2015 | 6 | 0.500 |
Why?
|
| Papillomavirus Vaccines | 2 | 2021 | 57 | 0.490 |
Why?
|
| Behavior Therapy | 1 | 2016 | 90 | 0.490 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 427 | 0.490 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 454 | 0.480 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 361 | 0.480 |
Why?
|
| Constipation | 1 | 2016 | 69 | 0.480 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2017 | 198 | 0.470 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 45 | 0.470 |
Why?
|
| Medication Adherence | 1 | 2016 | 141 | 0.470 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 216 | 0.460 |
Why?
|
| Residence Characteristics | 1 | 2016 | 204 | 0.460 |
Why?
|
| Counseling | 1 | 2016 | 169 | 0.460 |
Why?
|
| Quality Improvement | 3 | 2015 | 460 | 0.460 |
Why?
|
| Physicians | 2 | 2020 | 691 | 0.450 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 202 | 0.450 |
Why?
|
| Seizures | 1 | 2016 | 308 | 0.450 |
Why?
|
| Hypertension | 2 | 2017 | 757 | 0.450 |
Why?
|
| Carotid Stenosis | 1 | 2015 | 117 | 0.440 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2015 | 120 | 0.440 |
Why?
|
| Adult | 19 | 2024 | 27147 | 0.430 |
Why?
|
| Recurrence | 1 | 2016 | 1170 | 0.430 |
Why?
|
| Quality of Health Care | 3 | 2013 | 388 | 0.420 |
Why?
|
| Hepatitis C | 1 | 2015 | 176 | 0.420 |
Why?
|
| Sepsis | 1 | 2017 | 330 | 0.420 |
Why?
|
| Vaccination | 1 | 2014 | 281 | 0.400 |
Why?
|
| Disease Management | 5 | 2019 | 336 | 0.400 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 434 | 0.390 |
Why?
|
| Extraterrestrial Environment | 1 | 2011 | 1 | 0.390 |
Why?
|
| Meteoroids | 1 | 2011 | 1 | 0.390 |
Why?
|
| Stars, Celestial | 1 | 2011 | 1 | 0.390 |
Why?
|
| Lung | 1 | 2018 | 1310 | 0.390 |
Why?
|
| Health Care Reform | 1 | 2011 | 85 | 0.330 |
Why?
|
| Stroke | 2 | 2018 | 1006 | 0.330 |
Why?
|
| Female | 27 | 2024 | 47186 | 0.320 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 733 | 0.300 |
Why?
|
| United States | 8 | 2024 | 7188 | 0.290 |
Why?
|
| Health Maintenance Organizations | 3 | 1999 | 20 | 0.280 |
Why?
|
| Healthcare Disparities | 3 | 2010 | 432 | 0.270 |
Why?
|
| Attitude to Health | 2 | 1999 | 220 | 0.270 |
Why?
|
| Risk | 3 | 2024 | 657 | 0.270 |
Why?
|
| Male | 21 | 2024 | 43249 | 0.230 |
Why?
|
| Vaginal Smears | 2 | 2021 | 70 | 0.230 |
Why?
|
| Coronary Disease | 2 | 2024 | 261 | 0.220 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 117 | 0.220 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 59 | 0.220 |
Why?
|
| Aortic Diseases | 1 | 2024 | 102 | 0.210 |
Why?
|
| Sex Factors | 4 | 2021 | 1082 | 0.210 |
Why?
|
| Coronary Artery Disease | 3 | 2013 | 374 | 0.200 |
Why?
|
| Middle Aged | 16 | 2024 | 26555 | 0.200 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 175 | 0.200 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 804 | 0.200 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2021 | 4 | 0.190 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2016 | 54 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2380 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 863 | 0.190 |
Why?
|
| Gout Suppressants | 1 | 2021 | 35 | 0.190 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 39 | 0.190 |
Why?
|
| Physicians, Primary Care | 3 | 2012 | 104 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 2024 | 260 | 0.190 |
Why?
|
| Gout | 1 | 2021 | 75 | 0.180 |
Why?
|
| Postmenopause | 1 | 2021 | 102 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2018 | 2345 | 0.180 |
Why?
|
| Iron | 1 | 2021 | 173 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 110 | 0.180 |
Why?
|
| Smoking | 2 | 2015 | 630 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2021 | 163 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 404 | 0.170 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2020 | 8 | 0.170 |
Why?
|
| Morphinans | 1 | 2019 | 4 | 0.170 |
Why?
|
| Uterine Diseases | 1 | 2020 | 19 | 0.170 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 49 | 0.170 |
Why?
|
| Bone Marrow | 1 | 2021 | 446 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 76 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 64 | 0.160 |
Why?
|
| Acute Disease | 2 | 2021 | 855 | 0.160 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 360 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 34 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 243 | 0.150 |
Why?
|
| Guideline Adherence | 3 | 2021 | 234 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 301 | 0.150 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2018 | 31 | 0.150 |
Why?
|
| Urban Health Services | 2 | 2011 | 44 | 0.150 |
Why?
|
| Naltrexone | 1 | 2019 | 139 | 0.150 |
Why?
|
| Premenopause | 1 | 2018 | 57 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 164 | 0.150 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2018 | 147 | 0.150 |
Why?
|
| Luteinizing Hormone | 1 | 2018 | 167 | 0.150 |
Why?
|
| Informed Consent By Minors | 1 | 2017 | 2 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2024 | 723 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 763 | 0.150 |
Why?
|
| Pregnancy | 2 | 2016 | 3079 | 0.150 |
Why?
|
| Sex Reassignment Procedures | 1 | 2017 | 5 | 0.150 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 49 | 0.140 |
Why?
|
| Antidiarrheals | 1 | 2017 | 14 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2018 | 107 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 147 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 360 | 0.140 |
Why?
|
| Mental Competency | 1 | 2017 | 49 | 0.140 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 105 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 210 | 0.140 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2020 | 0.140 |
Why?
|
| Weight Loss | 1 | 2018 | 237 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 50 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 36 | 0.130 |
Why?
|
| Social Perception | 1 | 1997 | 94 | 0.130 |
Why?
|
| Probiotics | 1 | 2017 | 88 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2018 | 308 | 0.130 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2018 | 207 | 0.130 |
Why?
|
| Age Factors | 6 | 2021 | 1876 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2017 | 159 | 0.130 |
Why?
|
| Physician's Role | 1 | 1997 | 177 | 0.120 |
Why?
|
| Cause of Death | 1 | 2016 | 270 | 0.120 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 444 | 0.120 |
Why?
|
| Primary Prevention | 2 | 2024 | 82 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2017 | 352 | 0.120 |
Why?
|
| Aged | 9 | 2016 | 19574 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2018 | 852 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2014 | 88 | 0.110 |
Why?
|
| Pressure Ulcer | 2 | 2013 | 43 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2014 | 91 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2015 | 132 | 0.110 |
Why?
|
| Documentation | 2 | 2013 | 103 | 0.110 |
Why?
|
| Aging | 1 | 1999 | 732 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1609 | 0.110 |
Why?
|
| Critical Care | 1 | 2017 | 391 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 908 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2013 | 67 | 0.110 |
Why?
|
| Hospitalization | 3 | 2016 | 903 | 0.110 |
Why?
|
| Teaching | 2 | 2011 | 146 | 0.100 |
Why?
|
| Checklist | 1 | 2013 | 66 | 0.100 |
Why?
|
| Epilepsy | 1 | 2016 | 424 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2016 | 544 | 0.100 |
Why?
|
| Carbon Compounds, Inorganic | 1 | 2011 | 1 | 0.100 |
Why?
|
| Silicon Compounds | 1 | 2011 | 1 | 0.100 |
Why?
|
| Communication | 2 | 2019 | 462 | 0.100 |
Why?
|
| Diamond | 1 | 2011 | 3 | 0.100 |
Why?
|
| Nitrogen Isotopes | 1 | 2011 | 13 | 0.100 |
Why?
|
| Graphite | 1 | 2011 | 12 | 0.100 |
Why?
|
| Carbon Isotopes | 1 | 2011 | 75 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2016 | 594 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 803 | 0.100 |
Why?
|
| Adolescent | 3 | 2024 | 9411 | 0.100 |
Why?
|
| Education | 1 | 2011 | 58 | 0.100 |
Why?
|
| Patients | 1 | 2012 | 104 | 0.090 |
Why?
|
| Primary Health Care | 3 | 2011 | 357 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2011 | 179 | 0.090 |
Why?
|
| Patient Handoff | 1 | 2012 | 95 | 0.090 |
Why?
|
| Medical Informatics Applications | 1 | 2010 | 9 | 0.090 |
Why?
|
| Risk Factors | 3 | 2016 | 5608 | 0.090 |
Why?
|
| Patient Transfer | 1 | 2011 | 102 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2011 | 148 | 0.090 |
Why?
|
| Awareness | 1 | 2010 | 89 | 0.080 |
Why?
|
| Albuminuria | 1 | 2010 | 48 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 170 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2011 | 164 | 0.080 |
Why?
|
| Sigmoidoscopy | 1 | 1989 | 36 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 62 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 172 | 0.080 |
Why?
|
| Liver | 2 | 2024 | 1222 | 0.080 |
Why?
|
| Minority Groups | 2 | 2007 | 148 | 0.080 |
Why?
|
| Incidence | 3 | 2024 | 1599 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 200 | 0.080 |
Why?
|
| Hospitalists | 1 | 2010 | 140 | 0.080 |
Why?
|
| Inpatients | 1 | 2011 | 320 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2016 | 9400 | 0.070 |
Why?
|
| Mandatory Reporting | 1 | 2007 | 7 | 0.070 |
Why?
|
| Reimbursement, Incentive | 1 | 2007 | 37 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2010 | 328 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 270 | 0.070 |
Why?
|
| Program Development | 1 | 2007 | 130 | 0.070 |
Why?
|
| Hospitals, Teaching | 3 | 2011 | 118 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2017 | 2348 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 225 | 0.060 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2024 | 6 | 0.060 |
Why?
|
| Hepatitis B Vaccines | 1 | 2024 | 17 | 0.060 |
Why?
|
| Hepatitis B, Chronic | 1 | 2024 | 33 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 147 | 0.060 |
Why?
|
| Infant | 2 | 2024 | 3204 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2016 | 4367 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 106 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2021 | 407 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2024 | 91 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2024 | 3790 | 0.050 |
Why?
|
| Analgesics | 2 | 2021 | 119 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 6847 | 0.050 |
Why?
|
| American Heart Association | 1 | 2024 | 95 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 323 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1073 | 0.050 |
Why?
|
| American Cancer Society | 1 | 2021 | 12 | 0.050 |
Why?
|
| Uricosuric Agents | 1 | 2021 | 11 | 0.050 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2021 | 6 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 5378 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2024 | 482 | 0.050 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 28 | 0.050 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 56 | 0.050 |
Why?
|
| Uric Acid | 1 | 2021 | 136 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 1989 | 977 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2021 | 172 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 982 | 0.050 |
Why?
|
| Chicago | 3 | 1997 | 1452 | 0.050 |
Why?
|
| Exercise | 1 | 2024 | 329 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2024 | 960 | 0.050 |
Why?
|
| Logistic Models | 2 | 2011 | 1216 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2024 | 490 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 303 | 0.040 |
Why?
|
| Manipulation, Orthopedic | 1 | 1999 | 5 | 0.040 |
Why?
|
| Low Back Pain | 1 | 1999 | 41 | 0.040 |
Why?
|
| Child | 2 | 2024 | 7273 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Plants, Toxic | 1 | 1999 | 25 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 2022 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 317 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 6502 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2013 | 360 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 101 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 148 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 38 | 0.040 |
Why?
|
| Self Disclosure | 1 | 1997 | 32 | 0.040 |
Why?
|
| Research | 1 | 2019 | 252 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2024 | 8436 | 0.040 |
Why?
|
| Personality Inventory | 1 | 1997 | 109 | 0.040 |
Why?
|
| Health Promotion | 1 | 1999 | 164 | 0.030 |
Why?
|
| New Zealand | 1 | 2016 | 22 | 0.030 |
Why?
|
| Health Personnel | 1 | 1999 | 216 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 360 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 1997 | 280 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 102 | 0.030 |
Why?
|
| Mental Recall | 1 | 1997 | 163 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 125 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 198 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 897 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 421 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 498 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cognition | 1 | 1997 | 591 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 464 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 1265 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2013 | 246 | 0.020 |
Why?
|
| Videoconferencing | 1 | 2011 | 16 | 0.020 |
Why?
|
| Models, Educational | 1 | 2011 | 49 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 194 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2011 | 47 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 150 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1997 | 1753 | 0.020 |
Why?
|
| Bedding and Linens | 1 | 2011 | 13 | 0.020 |
Why?
|
| Personnel, Hospital | 1 | 2011 | 30 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 854 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 852 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 61 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 60 | 0.020 |
Why?
|
| Patient Preference | 1 | 2011 | 119 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 219 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 261 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2510 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2010 | 85 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 590 | 0.020 |
Why?
|
| Patient Participation | 1 | 2011 | 227 | 0.020 |
Why?
|
| Perception | 1 | 2010 | 181 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 332 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2010 | 318 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2012 | 364 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2682 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 887 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2011 | 281 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 681 | 0.020 |
Why?
|
| Data Collection | 1 | 1989 | 377 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1989 | 313 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2375 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1989 | 481 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3716 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 348 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2011 | 800 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2904 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 572 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 26 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 2004 | 28 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 3029 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 3825 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 332 | 0.010 |
Why?
|
| Medicare | 1 | 2006 | 432 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 791 | 0.010 |
Why?
|
| Manipulation, Spinal | 1 | 1999 | 2 | 0.010 |
Why?
|
| Physical Therapy Modalities | 1 | 1999 | 84 | 0.010 |
Why?
|
| Echocardiography | 1 | 2004 | 950 | 0.010 |
Why?
|
| Mammography | 1 | 1997 | 470 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 2785 | 0.010 |
Why?
|